iLääkärit has started a collaboration with HippocrAItes to utilize the Hippo Health Platform in...
Hippo Health Platform gains official market approval in Finland
Hippo Health Platform has received official approval for use in the Finnish healthcare sector from Valvira, the National Supervisory Authority for Welfare and Health in Finland.
This approval confirms that the platform meets Finland’s national requirements for data security, interoperability, and regulatory compliance in the health and social care system.
A1 classification validates that Hippo Health Platform:
- Is approved for clinical use in Finnish social and healthcare service organizations
- Complies with Finnish and EU data protection and interoperability standards
- Is compatible with national services, including the Kanta system
- Is validated for primary care
“Valvira’s approval enables the clinical use of the Hippo Health Platform in Finland. This marks the first step in the platform’s commercialization. We have now launched pilot projects aimed at validating the platform’s impact on healthcare professionals’ workflows. We will share the results of the pilot in October 2025,” confirms Juuso Haavisto, CEO of HippocrAItes.
Categories A1-A3 in Astori-register
Hippo Health Platform was approved for Category A1 classification.
• Information security assessment is required
• Does not require interoperability testing
• May include integration with the Kanta services (National Health Data Repository) via another system
• Example: data storage service or digital self-service platform
• Connects directly to the Kanta services
• Does not independently fulfill all national social and healthcare (SOTE) requirements
• Example: application for sending electronic prescriptions
• Complies with all Kanta integration requirements
• Widely used for managing clinical data
• Example: a hospital's electronic patient record system
For more information and interview requests:
Juuso Haavisto
CEO
juuso.haavisto@hippocraites.fi
tel. +358 50 351 1925
HippocrAItes
Join us at our Future Health event on October 2, 2025, in Meilahti, where we’ll present the pilot results!